Development of a Vaccine for HIVAIDS: Cellular Immunity

HIV/艾滋病疫苗的开发：细胞免疫

• 批准号: 9153760
• 负责人: Marjorie Robert-Guroff
• 金额: $ 33.98万
• 依托单位: DIVISION OF BASIC SCIENCES - NCI
• 依托单位国家: 美国
• 资助国家: 美国
• 起止时间: 至
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/9153760
• 关键词: AIDS Vaccines; Adenovirus Vector; Adenoviruses; Anti-Retroviral Agents; Antibodies; Antibody Response; Attenuated Live Virus Vaccine; B-Cell Development; Biological Models; Blood; Cell Line; Cell-Mediated Cytolysis; Cells; Cellular Immunity; Development; Effector Cell; Epithelial Cells; Exhibits; Female; Genes; Goals; HIV; HIV vaccine; Helper-Inducer T-Lymphocyte; Human; Immune; Immune response; Immunity; Immunization; Infection; Knowledge; Lead; Life; Macaca; Macaca mulatta; Measles; Mediating; Memory; Memory B-Lymphocyte; Modeling; Natural Immunity; Natural Killer Cells; Play; Poliomyelitis; Recombinants; Regimen; Role; SIV; Sex Characteristics; Site; Smallpox Vaccine; Surface; T-Lymphocyte; Time; Vaccination; Vaccines; Virus; Virus Diseases; Yellow Fever; base; design; env Gene Products; interest; male; mucosal site; pre-clinical; protective efficacy; replication competent adenoviral vector; response; simian human immunodeficiency virus; transmission process; vaccine development; vaccine trial; virus envelope

We are pursuing an HIV vaccine approach based on replication-competent Adenovirus (Ad)-recombinants. The rationale is based on the fact that live attenuated vaccines historically have been the most protective, eliciting essentially life-long immunity. Examples include vaccines for small pox, polio, measles, and yellow fever. We conduct pre-clinical vaccine studies in rhesus macaques and challenge with SIV or SHIV (a chimeric SIV virus containing an HIV envelope), systems that model HIV-infection of humans. We use a prime-boost strategy, first immunizing with a replicating adenovirus (Ad) vector carrying an HIV/SIV gene(s) followed by a boosting with HIV/SIV envelope protein. Ad replicates in epithelial cells that line mucosal inductive sites, and therefore elicits strong, persistent cellular immunity at mucosal effector sites as well as in the blood. We are currently conducting a pre-clinical vaccine study in macaques and are investigating cellular immune responses elicited by the vaccine regimen. Of particular interest is the question of whether female and male macaques developed different cellular immune responses to the vaccine components, as female macaques exhibited better protective efficacy compared to males. While sex differences have been seen with other vaccines, this is the first description of such a difference with a candidate AIDS vaccine. We have also collaborated on a study investigating innate and adaptive cellular responses to the replication-competent Ad vector, and have seen that innate immunity is somewhat suppressed while CD4-positive T cells are transiently activated following immunization. Because non-neutralizing antibody responses have been shown to be contributors to protective efficacy, we are studying effector cells which mediate some of these responses. We continue to explore CD4-dependent natural killer (NK) cells, previously shown to play a role in controlling SIV infection. Currently we are examining whether such responses can be boosted by envelope immunizations during the course of anti-retroviral therapy, and also whether vaccination elicits such responses. NK cells themselves are key effector cells in antibody-mediated cellular cytotoxicity, an activity that has been asociated with vaccine-elicited protective efficacy. Current studies include determining if NK cells in the rhesus macaque model contribute to mucosal immune protection and whether they exhibit memory. Gamma-delta T cells, effector cells that are especially important with regard to mucosal immune protection, are also under study. Finally T follicular helper cells (Tfh cells) are critical for promoting B cell development and maturation and induction of potent antibody responses. We are examining the effects of vaccination on development of such cells which should lead to memory B cells and more persistent antibody responses.

我们正在寻求基于可复制腺病毒（Ad）重组体的HIV疫苗方法。其理由是，减毒活疫苗在历史上一直是最具保护性的，基本上可以引发终身免疫。例如天花、小儿麻痹症、麻疹和黄热病的疫苗。我们在恒河猴中进行临床前疫苗研究，并用SIV或SHIV（一种含有HIV包膜的嵌合SIV病毒）进行攻击，这是一种模拟人类HIV感染的系统。我们使用初免-加强策略，首先用携带HIV/SIV基因的复制型腺病毒（Ad）载体免疫，然后用HIV/SIV包膜蛋白加强。腺病毒在粘膜诱导位点的上皮细胞中复制，因此在粘膜效应位点以及血液中激发强烈、持久的细胞免疫。我们目前正在猕猴中进行临床前疫苗研究，并正在调查疫苗方案引起的细胞免疫应答。特别令人感兴趣的是雌性和雄性猕猴是否对疫苗组分产生不同的细胞免疫应答的问题，因为雌性猕猴与雄性猕猴相比表现出更好的保护效力。虽然在其他疫苗中已经发现了性别差异，但这是第一次描述候选艾滋病疫苗的这种差异。我们还合作进行了一项研究，调查先天性和适应性细胞反应的复制能力的广告载体，并已看到，先天免疫是有点抑制，而CD 4阳性T细胞是短暂激活免疫后。由于非中和抗体反应已被证明是保护功效的贡献者，我们正在研究介导这些反应中的一些的效应细胞。我们继续探索CD 4依赖性自然杀伤（NK）细胞，以前显示在控制SIV感染中发挥作用。目前，我们正在研究在抗逆转录病毒治疗过程中是否可以通过包膜免疫来加强这种反应，以及疫苗接种是否可以增强这种反应。NK细胞本身是抗体介导的细胞毒性中的关键效应细胞，该活性与疫苗引起的保护功效相关。目前的研究包括确定恒河猴模型中的NK细胞是否有助于粘膜免疫保护以及它们是否表现出记忆。γ-δ T细胞是一种对粘膜免疫保护特别重要的效应细胞，也在研究之中。最后，T滤泡辅助细胞（Tfh细胞）对于促进B细胞发育和成熟以及诱导有效的抗体应答至关重要。我们正在研究疫苗接种对这些细胞发育的影响，这些细胞将导致记忆B细胞和更持久的抗体反应。